Shares of TapImmune Inc. (NASDAQ:MRKR) have received an average rating of “Buy” from the eight analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $12.07.
A number of equities analysts recently issued reports on MRKR shares. Nomura reiterated a “buy” rating and issued a $16.00 target price on shares of TapImmune in a research report on Tuesday, August 13th. Janney Montgomery Scott reiterated a “buy” rating on shares of TapImmune in a research report on Sunday, July 21st. ValuEngine upgraded shares of TapImmune from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. Finally, Zacks Investment Research lowered shares of TapImmune from a “hold” rating to a “sell” rating in a research report on Thursday, October 10th.
In other news, insider Peter L. Hoang acquired 10,000 shares of TapImmune stock in a transaction on Wednesday, August 14th. The stock was bought at an average cost of $4.62 per share, with a total value of $46,200.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 23.70% of the stock is currently owned by corporate insiders.
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
See Also: What is a dividend reinvestment plan?
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.